From The Motley Fool · The Motley Fool Team · · 50s
TL;DR: Tempus AI: 3 Key Takeaways for Long-Term Investors
Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors.
Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027. Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors. Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year.
- Q3 2026 Revenue
- Multiyear Biopharma Deals
- Oncology Pricing Boost
- Positive Adjusted EBITDA
Read the story version — the same reporting as a swipeable deck of 4 cards.




